Valérie Rouille

Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study

Guillaume Cartron, Zhaoyang Lu, Marion Baudard et al. · Journal of Clinical Oncology · 2008 · 83 citations · Full text

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

J.M. Rossi, Jérôme Moreaux, Dirk Hose et al. · British Journal of Cancer · 2009 · 77 citations · Full text

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

J.M. Rossi, Nathalie Fegueux, Éric Legouffe et al. · Bone Marrow Transplantation · 2005 · 59 citations · Full text

Hematological Malignancy, Allergy, Autoimmune Disease +9

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Rémi Letestu, Abdelmalek Dahmani, Marouane Boubaya et al. · Leukemia · 2020 · 25 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukemia +12

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Fabien Subtil et al. · The Lancet Haematology · 2019 · 21 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9